Naslov
Angioinvasive Aspergillosis in Patient with Langerhans Cell Histiocytosis

Autori
LJILJA A., Tekavec-Trkanjec J. , Bacalja J., Šimić M., Fazlić Džankić A.

Izvornik
Toraks 2019 / - Zagreb : Hrvatsko torakalno društvo

Vrsta, podvrsta
Ostale vrste radova, ostalo

Godina
2019

Ključne riječi
Langerhans Cell Histiocytosis, Angioinvasive Aspergillosis

Sažetak
Langerhans cell histiocytosis (LCH) is a rare lung disease of unknown etiology which is presented with multiple cysts and nodules predominately in upper lobes. It is typically associated with cigarette smoking. Diagnosis can be established by high-resolution computed tomography (HRCT), brochoalveolar lavage (BAL) and/or lung biopsy. While immunosuppressive treatment is acceptable for multisystem LHC, management of pulmonary LCH is not defined yet. Smoking cessation may lead to marked improvement, although relapses have also been described. Corticosteroids are frequently used in the management of pulmonary Langerhans cell histiocytosis (PLCH) despite limited evidence of benefit. Aspergilloma occures in pulmonary cysts and cavitary lesions. In immunocompromised patients aspergilloma may become angioinvasive, causing rapidly progressive and lethal disease if untreated. Angioinvasive aspergillosis is the most severe form of aspergillosis. It is a life-threatening condition that requires prompt treatment. CT findings include multiple or solitary nodules, alveolar infiltrates and cavitary lesions. A 'halo sign‘ may be seen in an early stage of disease around the nodule as a result of invasion into pulmonary vessels and is presented as an area of ground- glass opacity. Dissemination in other organs is also possible. Voriconazole is the treatment of choice for invasive pulmonary aspergillosis. In immunosuppressed patients with cystic lung disease and hemoptysis invasive aspergillosis must be considered as a possible cause of pulmonary bleeding.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA